Product News
Filter News
Found 260,912 articles
-
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™
5/8/2023
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting.
-
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/8/2023
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
-
Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries
5/7/2023
Shanghai Junshi Biosciences Co., Ltd announced a collaboration with Dr. Reddy’s Laboratories Limited to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy’s, also in Australia, New Zealand and other countries.
-
New Therapy for Rare Gastrointestinal Stromal Tumours Approved in Singapore
5/7/2023
Independent biopharmaceutical company Specialised Therapeutics Asia is pleased to announce that a new therapy to treat rare gastrointestinal stromal tumours shown to improve survival has been approved for use in Singapore.
-
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
5/6/2023
BeiGene announced the China National Medical Products Administration approved four applications for BRUKINSA, the company’s Bruton’s tyrosine kinase inhibitor, including two Supplemental New Drug Applications for treatment-naïve adults with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström's macroglobulinemia, and two Supplemental Applications for conversions from conditional approval to regular approval.
-
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
5/6/2023
Sight Sciences, Inc. announced the results from a 12-month retrospective sub-analysis of IOP-lowering medication use following the three most commonly performed, FDA approved MIGS procedures in patients with mild stage glaucoma.
-
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®
5/6/2023
AbbVie announced it will present 29 abstracts during the 2023 Digestive Disease Week Annual Meeting, May 6-9, 2023, being held in Chicago and virtually.
-
As competition eats away at profits for the wet age-related macular degeneration drug, Regeneron is diversifying its portfolio and pumping more money into research and development.
-
The companies said in first-quarter earnings calls that they want to restructure R&D, cut costs and shift away from high-risk drug development to focus areas. -
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
5/5/2023
Glaukos Corporation today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for iDose® TR (travoprost intraocular implant) is sufficiently complete to permit a substantive review.
-
Alcon Announces Results of 2023 Annual General Meeting
5/5/2023
Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2023 Annual General Meeting (AGM).
-
CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer
5/5/2023
CARsgen Therapeutics Holdings Limited announced that AB011 in combination with atezolizumab monoclonal antibody, Roche's PD-L1 checkpoint inhibitor, along with chemotherapy achieved IND clearance from the CDE for first-line treatment Claudin18.2 positive unresectable locally advanced, recurrent or metastatic gastric cancer/gastroesophageal junction cancer.
-
Public advisory - Bausch Health, Canada Inc. recalls all lots of Emerade epinephrine auto-injectors (0.3 mg and 0.5 mg strengths) due to possible device failure
5/5/2023
Emerade epinephrine auto-injectors, 0.3 mg (DIN 02458446) and 0.5 mg (DIN 02458454) Issue: Health products – Mechanical defect What to do: Return your Emerade auto-injector to your pharmacy for a suitable replacement as soon as possible.
-
Ultragenyx to Present at Bank of America’s 2023 Health Care Conference
5/5/2023
Ultragenyx Pharmaceutical Inc. today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at Bank of America’s 2023 Health Care Conference on Wednesday, May 10, 2023, at 9:20 a.m. PT.
-
Immunome Reports First Quarter 2023 Financial Results
5/5/2023
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
-
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)Study Did Not Meet Primary Endpoint
5/5/2023
FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not meet its primary efficacy endpoint.
-
Galapagos creates new subscription right plans - May 05, 2023
5/5/2023
Galapagos NV announced that its Board of Directors created 1,975,000subscription rights under new subscription rightplans for the benefit of certain members ofthe personnelof the company and its subsidiaries.
-
Editas Medicine Announces First Quarter 2023 Results and Business Updates
5/5/2023
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the first quarter 2023.
-
Viva Biotech's Recent Conferences & Events Review
5/5/2023
In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Research (AACR) Annual Meeting 2023, CPHI Japan 2023, PharmFuture 2023 Small Molecule Innovative Drug Future Leadership Summit, 2023 China - Yangzhou Biopharmaceutical Forum, 2023 Dalian Biopharmaceutical Industry Conference and International Gene Festival, etc.
-
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
5/5/2023
Dr. Reddy's Laboratories Ltd. today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of Lexiscan® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).